Polybrominated diphenyl ethers (PBDEs) have been found in human breast milk ([@b4-ehp0114-001179]; [@b23-ehp0114-001179], [@b24-ehp0114-001179]). This route is a potential excretion pathway for the mother and a route of exposure to these compounds for the neonate. Thus, the monitoring of breast milk provides data for not only adult exposure but also neonatal exposure.

Recently, an examination of Swedish human milk samples from 1972 to 1997 revealed exponential increases in the concentrations of PBDEs ([@b4-ehp0114-001179]; [@b23-ehp0114-001179], [@b24-ehp0114-001179]). Deca-BDE is used primarily in electrical and electronic applications (e.g., television housing, wire and cable insulation) and to a lesser extent in upholstery textiles. Penta-BDE was formerly used in flexible polyurethane foam for cushions. Octa-BDE was used in acrylonitrile-butadiene-styrene resins intended for business equipment housings. PBDEs are now found as residues in sediment ([@b38-ehp0114-001179]); in marine mammals, fish, and bird eggs ([@b3-ehp0114-001179]; [@b13-ehp0114-001179]; [@b45-ehp0114-001179]); and in the breast milk, serum, whole blood, and adipose tissue of humans ([@b5-ehp0114-001179]; [@b15-ehp0114-001179]; [@b18-ehp0114-001179]; [@b35-ehp0114-001179]; [@b41-ehp0114-001179]). In contrast to PBDEs, banning the production and use of polychlorinated biphenyls (PCBs) in the 1970s has decreased PCB serum levels and dietary exposure to PCBs since the 1980s ([@b15-ehp0114-001179]).

The aims of the present study were 2-fold. The first was to determine the current levels of PBDEs and PCBs in Japanese women of reproductive age and to analyze the effects of lifestyle and dietary habits on these levels. The second was to develop a quantitative structure--activity relationship (QSAR) model, which enables us to predict the relationship between serum and breast milk. The second aim addresses the importance of translatability between the serum and milk data.

Materials and Methods
=====================

Target populations
------------------

The present study was approved by the Ethics Committee of the Kyoto University Institutional Review Board, and appropriate written informed consent was obtained from all the participants before sample collection.

After obtaining formal informed consent, we collected blood and breast milk samples from mothers who had delivered and were lactating in maternity hospitals in four regions: Sendai city (population, 1 million) in Miyagi Prefecture, Takarazuka city (population, 250,000) in Hyogo Prefecture, Takayama city (population, 200,000) in Gifu Prefecture, and Shizunai-cho (population, 23,000) in Hokkaido Prefecture.

Collection of serum samples and breast milk samples
---------------------------------------------------

Milk samples were self-collected manually into breast pumps with glass containers at the individual hospitals and transferred to 50-mL polypropylene conical tubes (milk tube) that had been thoroughly rinsed with methanol and acetone before use; samples were kept frozen at --20°C. The target volume was \> 20 mL from each mother per sample. Blood samples (10 mL) were collected into two 5-mL vacuum blood collection polypropylene tubes (Venoject II; TERUMO Inc., Tokyo, Japan) (blood tube) from cubital vein by physicians or nurses. The blood and milk samples were shipped within 48 hr to Kyoto University. The serum samples were separated by centrifugation at 3,000*g* for 15 min, transferred to new blood tubes, and stored at --20°C in the Department of Health and Environmental Sciences, Kyoto University Graduate School of Medicine, until analysis.

When the milk samples were collected, we asked the mothers to fill out questionnaires that contained necessary items for milk surveillance ([@b16-ehp0114-001179]) and sources of exposure to PBDEs ([@b25-ehp0114-001179]; [@b30-ehp0114-001179]; [@b31-ehp0114-001179]; [@b47-ehp0114-001179]), including the duration of lactation, parity, residential history within the previous 5 years, lifestyle and habits, and indoor environment ([Supplemental](#SD1){ref-type="supplementary-material"} [Table 1](#t1-ehp0114-001179){ref-type="table"}; available online at <http://www.ehponline.org/docs/2006/9032/suppl.pdf>).

We prepared eight field blanks per site, each consisting of an empty milk tube and an empty blood tube. In addition, we prepared eight milk tube/blood tube pairs filled with 5 mL of distilled water at the sampling site as field operational blanks. All the blank samples were sent to Kyoto University and run through complete extraction, cleanup, and analysis procedures.

Serum extraction
----------------

The internal standard from mono- to deca-^13^C~12~-PBDE and mono to deca-^13^C~12~-PCB was spiked in the serum (3 g) and extracted by liquid--liquid extraction following the method of [@b41-ehp0114-001179], [@b40-ehp0114-001179]. Briefly, in the serum spiked with internal standard, 3 mL ammonium sulfate, 1 mL ethanol, and 2 mL hexane were mixed and extracted twice. The final extract was washed with hexane-washed water, dehydrated with sodium sulfate, and concentrated to 5 mL for further cleanup.

Milk extraction
---------------

The internal standard from mono- through deca-^13^C~12~-PBDE and mono- to deca-^13^C~12~-PCB was spiked in the milk (3 g) and extracted by liquid--liquid extraction. Briefly, in the milk spiked with internal standard, 1 mL saturated potassium oxalate, 2 mL ethanol, 2 mL diethyl ether, and 1 mL hexane were mixed and extracted twice. The final extract was washed with 1 mL of 5% sodium chloride and then dehydrated with sodium sulfate and concentrated to 5 mL for further cleanup.

Cleanup of serum and milk
-------------------------

The 5-mL extract from serum or milk was subjected to multilayer Florisil silica gel column cleanup ([@b41-ehp0114-001179], [@b40-ehp0114-001179]). The multilayer cleaned samples were further concentrated to the injection volume by nitrogen purge.

Identification and quantification of PBDEs and PCBs
---------------------------------------------------

We used high-resolution gas chromatography (HRGC; HP6890, Agilent)/high-resolution mass spectrometry (HRMS; Autospec Ultima; Micromass, Cary, NC, USA) for analysis of PBDEs and PCBs. Details on the HRGC/HRMS program are reported elsewhere ([@b41-ehp0114-001179], [@b40-ehp0114-001179]). Briefly, for PBDE analysis we used either a BP-1 \[15 m × 0.25 mm i.d. (0.1 μm); SGE Analytical Science Pty. Ltd., Austin, TX, USA\] column or a ENV-5MS \[15 m × 0.25 mm i.d. (0.1 μm)\] column. The column was used with a temperature program of 120°C (1 min), increased 20°C/min to 160°C (0 min), 10°C/min to 260°C (0 min), and 20°C/min to 300°C (8 min). For analysis of PCBs, we used an HT-8 PCB column (60 m × 0.25 mm i.d.; SGE Analytical), which was used with an initial temperature of 150°C (0 min), increased 20°C/min to 200°C (0 min), 5°C/min to 260°C (0 min), and 10°C/min to 300°C (11.5 min). We used an on-column injection program with a 2-μL sample injection volume and with a resolution of *M*/Δ*M* \> 10,000 (10% valley). We determined the individual and total concentrations of 13 PBDE congeners \[ΣPBDE~13~; International Union of Pure and Applied Chemistry (IUPAC) congeners 15, 28, 47, 99, 100, 153, 154, 183, 196, 197, 206, 207, and 209\] and 15 PCB congeners (ΣPCB~15~; IUPAC congeners 74, 99, 118, 138, 146, 153, 156, 163/164, 170, 180, 182/187, 194, 199, 206, and 209).

The limit of detection (LOD) for each PCB congener was 1 pg/g in both serum and breast milk. The LOD of each PBDE congener in serum and milk was between 0.2 and 2 pg/g for di-BDE to hepta-BDE and between 0.3 and 2 pg/g for octa-BDE to deca-BDE. The serum and milk concentrations of PCBs and PBDEs were expressed as nanograms per gram lipid. The lipid content in the serum samples was estimated from the total cholesterol and triglyceride concentrations ([@b27-ehp0114-001179]). The lipid content of the milk samples was determined from 2 mL crude extracts by gravimetric method.

Quality assurance and quality control
-------------------------------------

PBDE and PCB (native as well as ^13^C~12~−labeled) standard solutions that contained the major congeners of mono-BDE or mono-CB to deca-BDE or deca-CB (\> 95% pure) were purchased from Wellington Laboratories (Guelph, Ontario, Canada). The average recovery of individual PBDE congeners was 54--84% in serum (*n* = 100) and 54--103% in milk (*n* = 100), and the average recovery of PCB congeners was 61--79% in serum (*n* = 100) and 68--115% in milk (*n* = 100). The coefficient of variation for each determination was within 15% for both PBDEs and PCBs.

For all field blanks and field operational blanks, all PBDE and PCB congeners were \< LOD. Operational blank tubes filled with 5 mL distilled water in an analytical laboratory (Shimadzu Techno-Research Inc., Kyoto, Japan) were also prepared for each eight-sample batch. These operational blanks were \< LOD for all PBDE and PCB congeners in both the serum and milk batches. Thus, we did not correct the results for background levels.

Structure--activity relationship
--------------------------------

For the QSAR analysis, we chose congeners that were detected in \> 50% of both the serum and milk samples. Theoretical molecular descriptors for the compounds, which included constitutional descriptors, atom-centered fragments, and molecular properties, such as hydrophilicity, molar refractivity, polar surface area, and octanol/water partition coefficient (*K*~ow~), were calculated using Dragon software (version 5.0; Milano Chemo Metrics and QSAR Research Group, Milan, Italy) and ADMET Predictor 1.2.3 (Simulations Plus, Lancaster, CA, USA). The *K*~ow~ calculated by Hansch's method (CLogP) and the molar refractivity calculated by Hansch's method (CMR) were calculated using Web applications provided by Daylight Chemical Information Systems (Aliso Viejo, CA, USA). Descriptors that had a bivariate correlation \> 0.70 were removed.

We performed a stepwise multiple linear regression analysis using the SAS statistical package (version 8.2; SAS Institute Inc., Cary, NC, USA). All independent variables in the regressions had a significance of at least 95%, based on Student's *t*-score.

Statistical analysis
--------------------

Statistical analyses were conducted after logarithmic transformation of the concentrations of the PBDEs and PCBs. We tested differences between means by analysis of variance (ANOVA) or Student's *t*-test when appropriate. A stepwise multiple regression analysis was used to explore determinants for the serum and milk levels of contaminants using a forward--backward stepwise regression model (*F*-statistic to enter and stay in the model with a *p*-value of \< 0.25). We evaluated the determinants for PBDEs and PCBs in serum and breast milk using a conservative approach based on multiple comparisons of the questionnaire items. Thus, a *p*-value of \< 0.01 was considered significant in the multiple regression analysis for the questionnaire items. For the other analyses, a *p*-value of \< 0.05 was considered significant. All statistical analyses were carried out with SAS software.

Results
=======

Demographic features of the participants
----------------------------------------

On the whole, there were 20 participants from Hokkaido, 40 from Miyagi, 20 from Gifu, and 9 from Hyogo. The ages of the participants ranged from 20 to 43 years (mean ± SD, 30.1 ± 4.6 years). The results of the questionnaires are summarized in [Table 1](#t1-ehp0114-001179){ref-type="table"}.

Determination of PBDEs and PCBs in serum and milk
-------------------------------------------------

The concentrations of some congeners in the human samples were \< LOD. We treated these samples as 0 pg/g lipid when we calculated the total amount.

The distributions of ΣPBDE~13~ in serum and milk followed log-normal distributions (Kolmogorov-Smirnov-Lilliefors test, *p* \> 0.05). The geometric mean (GM) values for the total amounts of ΣPBDE~13~ in the milk and serum samples were 1.56 and 2.89 ng/g lipid, respectively ([Table 2](#t2-ehp0114-001179){ref-type="table"}). The PBDE congener levels and detection rates for milk and serum are available online ([Supplemental](#SD1){ref-type="supplementary-material"} [Tables 2](#t2-ehp0114-001179){ref-type="table"} and [3](#t3-ehp0114-001179){ref-type="table"}, respectively; <http://www.ehponline.org/docs/2006/9032/suppl.pdf>). BDE-209 was the predominant congener in serum and accounted for 38% of the total PBDEs but was a minor congener in milk and accounted for 8% of the ΣPBDE~13~ ([Figure 1A](#f1-ehp0114-001179){ref-type="fig"}). In milk, BDE-47 and BDE-153 were the major congeners and accounted for 28 and 23% of the total PBDEs, respectively.

The distributions of the ΣPCB~15~ in serum and milk also followed log-normal distributions (Kolmogorov-Smirnov-Lilliefors test, *p* \> 0.05). The GM values for ΣPCB~15~ in the milk and serum samples were 63.9 and 37.5 ng/g lipid, respectively ([Table 2](#t2-ehp0114-001179){ref-type="table"}). The PCB congener levels and detection rates for milk and serum are available online ([Supplemental](#SD1){ref-type="supplementary-material"} [Tables 4](#t4-ehp0114-001179){ref-type="table"} and 5, respectively; <http://www.ehponline.org/docs/2006/9032/suppl.pdf>). CB-153, CB-138, and CB-180 were the major congeners in both milk and serum (30, 17, and 13% of the total for milk and 28, 16, and 15% of the total for serum, respectively) ([Figure 1B](#f1-ehp0114-001179){ref-type="fig"}).

It should be noted that approximately the same concentrations of the lighter PBDEs (e.g., BDE-47) are present in serum and milk, but BDE-209 is found at 10 times lower concentrations in milk than in serum ([Supplemental](#SD1){ref-type="supplementary-material"} [Tables 2](#t2-ehp0114-001179){ref-type="table"} and [3](#t3-ehp0114-001179){ref-type="table"}; available online at <http://www.ehponline.org/docs/2006/9032/suppl.pdf>). Likewise, almost double the serum concentration of CB-153 is found in milk, whereas more than double the milk concentration of CB-209 is found in serum ([Supplemental](#SD1){ref-type="supplementary-material"} [Tables 4](#t4-ehp0114-001179){ref-type="table"} and 5; available online at <http://www.ehponline.org/docs/2006/9032/suppl.pdf>).

Determinants for PCBs and PBDEs in serum and milk
-------------------------------------------------

We found significant correlations between ΣPCB~15~ and ΣPBDE~13~ levels in both milk and serum (*r*^2^ = 0.194, *p* \< 0.0001 for milk; *r*^2^ = 0.1808, *p* \< 0.0001 for serum). There were also significant geographic differences in ΣPBDE~13~ concentrations in milk and serum (ANOVA, *p* = 0.00095 and *p* = 0.00030, respectively; [Table 2](#t2-ehp0114-001179){ref-type="table"}). The GM for ΣPBDE~13~ in the milk samples was higher for Hokkaido than for the other areas \[Tukey's honest significant difference (HSD) test, *p* \< 0.05\], whereas the GM for ΣPBDE~13~ in serum samples was higher in Miyagi than in Gifu (Tukey's HSD test, *p* \< 0.05). The PCB levels also exhibited geographic differences (ANOVA, *p* = 0.0029 for milk and *p* \< 0.0001 for serum; [Table 2](#t2-ehp0114-001179){ref-type="table"}). The GMs for ΣPBDE~13~ in both milk and serum samples were higher in Miyagi and Hyogo than in Gifu (Tukey's HSD test, *p* \< 0.05).

Multiple regression analysis revealed that the geographic factor was the primary determinant for the PBDE levels in both milk and serum (data not shown). In contrast, nursing duration was the significant determinant for PCB levels in both serum and milk (data not shown). To investigate the possible association between hospitals and nursing durations, we tested whether nursing duration was a determinant for PBDE or PCB levels within a single hospital. The nursing duration was correlated with the ΣPBDE~13~ in serum in Miyagi (*n* = 38, Kendall's τ= −0.266, *p* = 0.0187) and the ΣPCB~15~ in both serum and milk in Miyagi (*n* = 38, Kendall's τ= --0.426, *p* = 0.0002, and Kendall's τ= --0.312, *p* = 0.0059, respectively; data not shown).

QSAR analysis
-------------

BDE-154, BDE-183, BDE-196, and BDE-206 were eliminated from the analysis because of their low detection rates in serum and/or milk (\< 50%). In the first step, we calculated the mean ratios of milk concentrations (nanograms per gram lipid) to serum concentrations (nanograms per gram lipid) for individual congeners from milk and serum as surrogates for their partition coefficients ([Supplemental](#SD1){ref-type="supplementary-material"} Table 6; available online at <http://www.ehponline.org/docs/2006/9032/suppl.pdf>). Using these mean ratios, we then applied a multiple linear regression analysis using various descriptors for individual PCB and PBDE congeners. The descriptors that have been used for QSAR analysis include hydrophobicity \[log *K*~ow,~ CLogP, (octanol/water partition coefficient calculated by Hansch's method), and MLogP (octanol/water partition coefficient calculated by Moriguchi's method)\], size \[MW (molecular weight) and MgVol (molar volume calculated by McGowan's method)\], polarizability \[CMR, (molar refractivity calculated by Hansch's method), AMR (calculated by Ghose and Crippen's method), and PolarizG (polarizability calculated by Glen's method)\], and constitutional descriptors \[TPSA (topologic polar surface area), HBA (number of hydrogen-bond acceptors), nCL (number of chlorines), and nBR (number of bromines)\] ([Table 3](#t3-ehp0114-001179){ref-type="table"}) ([@b1-ehp0114-001179]; [@b7-ehp0114-001179]; [@b8-ehp0114-001179]; [@b17-ehp0114-001179]; [@b21-ehp0114-001179]).

[Table 3](#t3-ehp0114-001179){ref-type="table"} summarizes the correlation coefficients between pairs of the descriptors, together with regression coefficients for each descriptor. Regarding PCB and PBDE congeners, the descriptors for hydrophobicity (log *K*~ow~, CLogP, and MLogP), molecular size (MW and MgVol), and polarizability (CMR, AMR, and PolarizG) were collinear, and each correlated well with the milk/serum partition coefficient (log *P*). We explored the combination of the descriptors that exhibited the highest multiple regression coefficient (*r*) and obtained the following equation:
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Because partition coefficients have been reported to be dependent on the nursing period ([@b16-ehp0114-001179]), we tested the relationship between the predicted and observed mean partition coefficients for three nursing durations ([Figure 2](#f2-ehp0114-001179){ref-type="fig"}). For nursing durations ≤10 weeks, the partition coefficients predicted by the QSAR analysis agreed with the observed values. However, the coefficient of *x* was smaller for nursing durations \> 10 weeks, suggesting that the prediction became weaker for longer nursing periods.

Discussion
==========

In this article we have reported the current levels of ΣPBDE~13~, including deca-BDE (BDE-209), in serum and milk from Japanese mothers. We found that BDE-209 was the most abundant congener in serum but a minor congener in milk. Its abundance in serum suggests that wide industrial use of BDE-209 may result in exposure ([@b44-ehp0114-001179]). Thus, low partitioning of this congener from serum to milk might have resulted in the underestimation of human adult exposure to deca-BDE, if the exposure monitoring system used was dependent solely on milk surveillance.

[Table 4](#t4-ehp0114-001179){ref-type="table"} shows the recent data on PBDEs in breast milk and serum from 12 countries. The current total PBDE levels in Japan are significantly lower than those in most Western countries ([@b14-ehp0114-001179]; [@b19-ehp0114-001179]; [@b20-ehp0114-001179]; [@b22-ehp0114-001179]; [@b26-ehp0114-001179]; [@b28-ehp0114-001179]; [@b29-ehp0114-001179]; [@b32-ehp0114-001179]; [@b34-ehp0114-001179]; [@b37-ehp0114-001179]) and appear to be approximately equal to those of Sweden ([@b10-ehp0114-001179]; [@b14-ehp0114-001179]; [@b18-ehp0114-001179]; [@b36-ehp0114-001179]), Spain ([@b33-ehp0114-001179]), Italy ([@b12-ehp0114-001179]), Germany ([@b43-ehp0114-001179]), and Finland ([@b39-ehp0114-001179]). Even for BDE-209, exposure was relatively lower in Japan than in the United States and Mexico. Even taking into account the variations in the measured PBDE congeners, the above argument holds true.

We investigated factors that may influence the PBDE or PCB levels in serum and milk. We found that the geographic factor was the major determinant of PBDE levels in Japan. In contrast, current nursing duration was most significant for PCBs. Because the current nursing duration was confounded by the variation in the timing of milk collection in the different hospitals, one could argue that the apparent differences might be explained partly by the geographic factor. However, the current nursing duration remained significant for both PBDEs and PCBs even within sample series from a single hospital, indicating that their concentrations became lower as the nursing period became longer, as previously reported by others ([@b48-ehp0114-001179]).

Human milk or serum surveillance is typically performed to monitor temporal changes in the concentrations of environmental chemicals or to compare the concentrations of environmental chemicals among different populations. However, only a few trials to bridge the values for serum and milk have been carried out for environmental chemicals ([@b9-ehp0114-001179]). In contrast, there have been several models and methods for predicting drug transfer into human milk ([@b6-ehp0114-001179]) using the QSAR approach. We applied the same approach for PCBs and PBDEs. The analysis revealed that CLogP and HBA are sufficient predictors of the transfer from serum to milk. For PBDEs, the oxygen atom bridging two halogenated aryl groups, which functions as a hydrogen-bond acceptor, appeared to reduce the transfer from serum to milk. On the other hand, the model only weakly predicted the partition coefficients in the later stages of nursing (≥11 weeks), as suggested by [@b48-ehp0114-001179]. With the limitation of the nursing period as a mode of prediction by Equation 1, the present model can be practically used for translating the concentrations in the two samples.

Conclusion
==========

BDE-209 was the PBDE detected at the highest concentration in serum of Japanese lactating women, but its excretion in milk was lower than that of the lower brominated diphenyl ethers BDE-47 and BDE-153. Geographic location within Japan and the duration of nursing were discernible determinants for levels of PBDEs and PCBs in human serum and milk, respectively. The levels of PBDEs in Japan were much lower than those in the United States, Canada, and Mexico but similar to those in European countries. The application of QSAR for the structure--partition relationship revealed that the values for serum and milk are translatable to each other.

[Supplemental](#SD1){ref-type="supplementary-material"} Material is available online at <http://www.ehponline.org/docs/2006/9032/suppl.pdf>
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![Distributions of PBDE (*A*) and PCB (*B*) congeners in milk and serum from the 89 participants (mean ± SE). The levels of each congener are indicated as the mean percentage of the ΣPBDE or ΣPCB concentration.](ehp0114-001179f1){#f1-ehp0114-001179}

![Predicted and observed partition coefficients (milk/serum) of PBDE and PCB congeners by nursing duration. (*A*) Weeks 0--1. (*B*) Weeks 2--10. (*C*) Weeks 11--88. The *y*-axis represents the predicted partition coefficient, and the *x*-axis represents the ratio of the observed milk concentration to the observed serum concentration (mean ± SE). For (*A*), the relationship between the predicted (*y*) and observed (*x*) partition coefficients was *y* = 1.210*x* -- 0.237 (*r* = 0.866, *p* \< 0.001, *n* = 26); for weeks 2--10 (*B*), *y* = 1.028*x* + 0.082 (*r* = 0.921, *p* \< 0.001, *n* = 38); for weeks 11--88 (*C*), *y* = 0.717*x* + 0.233 (*r* = 0.824, *p* \< 0.001, *n* = 25).](ehp0114-001179f2){#f2-ehp0114-001179}

###### 

Characteristics of the participants.

                                                Total         Hokkaido     Miyagi        Gifu          Hyogo        *p*-Value
  --------------------------------------------- ------------- ------------ ------------- ------------- ------------ ----------------------------------------------------------
  No. of participants                           89            20           40            20            9            
  Age (years)                                                                                                       
   20--29                                       45            13           19            10            3            0.66
   30--39                                       40            6            20            9             5            
   40--49                                       4             1            1             1             1            
   Mean ± SD                                    30.1 ± 4.6    27.7 ± 4.8   30.7 ± 4.1    30.0 ± 4.3    33.3 ± 4.5   0.01
  Parity (mean ± SD)                            1.45 ± 0.6    1.55 ± 0.8   1.33 ± 0.5    1.55 ± 0.7    1.56 ± 0.5   0.43
  Nursing week at milk collection (mean ± SD)   13.6 ± 22.1   1.55 ± 1.6   12.0 ± 18.6   33.4 ± 30.3   3.11 ± 0.9   \< 0.0001[\*](#tfn1-ehp0114-001179){ref-type="table-fn"}
  Occupation \[no. (%)\]                                                                                            
   Housewife                                    50 (56.2)     13 (65.0)    21 (52.5)     9 (45.0)      7 (77.8)     0.21
   Office worker                                16 (18.0)     1 (5.0)      11 (27.5)     4 (20.0)      0            
   Technical professional                       22 (24.7)     5 (25.0)     8 (20.0)      7 (35.0)      2 (22.2)     
   Farmer                                       1 (1.1)       1 (5.0)      0             0             0            
  Use electronic equipment \[no. (%)\]                                                                              
   Personal computer                                                                                                
    Frequent use                                43 (48.3)     4 (20.0)     27 (67.5)     8 (40.0)      4 (44.4)     0.004[\*](#tfn1-ehp0114-001179){ref-type="table-fn"}
    Rare use                                    46 (51.7)     16 (80.0)    13 (32.5)     12 (60.0)     5 (55.6)     
   Mobile phone                                                                                                     
    Frequent use                                58 (65.2)     13 (65.0)    26 (65.0)     15 (75.0)     4 (44.4)     0.47
    Rare use                                    31 (34.8)     7 (35.0)     14 (35.0)     5 (25.0)      5 (55.6)     
   Television                                                                                                       
    Frequent use                                69 (77.5)     17 (85.0)    29 (72.5)     17 (85.0)     6 (66.7)     0.36
    Rare use                                    20 (22.5)     3 (15.0)     11 (27.5)     3 (15.0)      3 (33.3)     
  Household furnishings \[no. (%)\]                                                                                 
   Carpet                                                                                                           
    Frequent use                                65 (73.0)     18 (90.0)    28 (70.0)     12 (60.0)     7 (77.8)     0.14
    Rare use                                    24 (27.0)     2 (10.0)     12 (30.0)     8 (40.0)      2 (22.2)     
   Cushions                                                                                                         
    Frequent use                                52 (58.4)     10 (50.0)    24 (60.0)     10 (50.0)     8 (88.9)     0.15
    Rare use                                    37 (41.6)     10 (50.0)    16 (40.0)     10 (50.0)     1 (11.1)     
   Sofa                                                                                                             
    Frequent use                                66 (74.2)     18 (90.0)    30 (75.0)     11 (55.0)     7 (77.8)     0.08
    Rare use                                    23 (25.8)     2 (10.0)     10 (25.0)     9 (45.0)      2 (22.2)     
   Curtains                                                                                                         
    Frequent use                                81 (91.0)     18 (90.0)    37 (92.5)     17 (85.0)     9 (100.0)    0.46
    Rare use                                    8 (9.0)       2 (10.0)     3 (7.5)       3 (15.0)      0 (0.0)      
   Blinds                                                                                                           
    Frequent use                                42 (47.2)     10 (50.0)    19 (47.5)     9 (45.0)      4 (44.4)     0.99
    Rare use                                    47 (52.8)     10 (50.0)    21 (52.5)     11 (55.0)     5 (55.6)     
  Fish consumption (\> once/week) \[no. (%)\]                                                                       
   Yellowtail and young yellowtail                                                                                  
    Yes                                         14 (15.7)     0 (0.0)      4 (10.0)      8 (40.0)      2 (22.2)     0.003[\*](#tfn1-ehp0114-001179){ref-type="table-fn"}
    No                                          75 (84.3)     20 (100.0)   36 (90.0)     12 (60.0)     7 (77.8)     
   Mackerel                                                                                                         
    Yes                                         34 (38.2)     5 (25.0)     12 (30.0)     10 (50.0)     7 (77.8)     0.03
    No                                          55 (61.8)     15 (75.0)    28 (70.0)     10 (50.0)     2 (22.2)     
   Salmon                                                                                                           
    Yes                                         56 (62.9)     13 (65.0)    30 (75.0)     9 (45.0)      4 (44.4)     0.30
    No                                          33 (37.1)     7 (35.0)     10 (25.0)     11 (55.0)     5 (58.6)     
  Smoking status \[no. (%)\]                                                                                        
   Nonsmoker                                    56 (62.9)     10 (50.0)    27 (67.5)     11 (55.0)     8 (88.9)     0.17
   Ex-smoker                                    25 (28.1)     8 (40.0)     10 (25.0)     7 (35.0)      0 (0.0)      
   Current smoker                               4 (4.5)       2 (10.0)     1 (2.5)       1 (5.0)       0 (0.0)      
   Passive smoker                               4 (4.5)       0 (0.0)      2 (5.0)       1 (5.0)       1 (11.1)     
  Alcohol consumption \[no. (%)\]                                                                                   
   Nondrinker                                   35 (39.3)     12 (60.0)    12 (30.0)     7 (35.0)      4 (44.4)     0.21
   Ex-drinker                                   48 (53.9)     7 (35.0)     26 (65.0)     10 (50.0)     5 (55.6)     
   Current drinker                              6 (6.7)       1 (5.0)      2 (5.0)       3 (15.0)      0 (0.0)      

*p* \< 0.01; *p-*values were calculated for continuous values by ANOVA and for categorical values for the chi-square test or Fisher's exact test.

###### 

Concentrations (ng/g lipid) of PBDEs or PCBs in human milk or serum samples.

  Measure/area    No. of participants   GM (GSD)*[a](#tfn3-ehp0114-001179){ref-type="table-fn"}*   Mean ± SD        Range         Q25    Median   Q75
  --------------- --------------------- ---------------------------------------------------------- ---------------- ------------- ------ -------- -------
  PBDE in milk                                                                                                                                    
   Hokkaido       20                    2.23 (1.47)^A^                                             2.39 ± 0.94      1.02--4.55    1.72   2.22     2.97
   Miyagi         40                    1.42 (1.56)^B^                                             1.55 ± 0.65      0.49--3.11    1.06   1.46     1.98
   Gifu           20                    1.45 (1.51)^B^                                             1.58 ± 0.71      0.82--3.30    1.01   1.40     2.00
   Hyogo          9                     1.30 (1.65)^B^                                             1.45 ± 0.70      0.66--2.38    0.83   1.31     2.31
    Total         89                    1.56 (1.59)                                                1.74 ± 0.81      0.49--4.55    1.13   1.54     2.24
  PBDE in serum                                                                                                                                   
   Hokkaido       20                    2.75 (1.47)^AB^                                            2.93 ± 1.04      1.04--5.43    2.24   2.96     3.50
   Miyagi         40                    3.64 (1.66)^B^                                             4.21 ± 3.14      1.33--21.19   2.68   3.56     4.93
   Gifu           20                    2.06 (1.55)^A^                                             2.24 ± 0.92      0.74--4.50    1.45   2.34     2.71
   Hyogo          9                     2.52 (1.76)^AB^                                            2.84 ± 1.32      0.76--5.38    1.78   3.13     3.41
    Total         89                    2.89 (1.68)                                                3.34 ± 2.37      0.74--21.19   2.16   2.99     3.76
  PCB in milk                                                                                                                                     
   Hokkaido       20                    58.91 (1.53)^AB^                                           64.50 ± 29.91    20--160       50.0   60.0     71.0
   Miyagi         40                    70.75 (1.56)^B^                                            78.48 ± 40.66    29--250       54.5   72.5     89.3
   Gifu           20                    47.24 (1.76)^A^                                            54.95 ± 30.17    18--130       33.3   51.5     72.0
   Hyogo          9                     94.64 (1.75)^B^                                            109.44 ± 58.41   39--190       65.0   93.0     170.0
    Total         89                    63.86 (1.69)                                               73.18 ± 40.90    18--250       47.0   65.0     88.0
  PCB in serum                                                                                                                                    
   Hokkaido       20                    35.92 (1.61)^AB^                                           40.65 ± 24.49    14--130       29.8   35.0     49.0
   Miyagi         40                    45.80 (1.72)^B^                                            53.00 ± 31.24    15--170       32.8   51.0     62.3
   Gifu           20                    22.26 (1.88)^A^                                            27.25 ± 18.86    7.9--82       14.0   22.0     35.5
   Hyogo          9                     54.32 (1.85)^B^                                            65.22 ± 40.67    23--130       34.0   50.0     89.0
    Total         89                    37.52 (1.89)                                               45.67 ± 30.58    7.9--170      26.0   38.0     57.0

Abbreviations: GSD, geometric SD; Q25, first quartile; Q75, third quartile.

Different letters (A, B, or AB) indicate that the corresponding values are statistically different by Tukey's HSD test after ANOVA (p \< 0.05).

###### 

Correlation coefficients between pairs of molecular descriptors or log *P* for PCBs and PBDEs.

                log *K*~ow~   CLogP     MLogP     MW        MgVol     CMR       AMR       PolarizG   TPSA      HBA       nCL       nBR
  ------------- ------------- --------- --------- --------- --------- --------- --------- ---------- --------- --------- --------- ---------
  log *K*~ow~   1                                                                                                                  
  CLogP         0.978         1                                                                                                    
  MLogP         0.899         0.948     1                                                                                          
  MW            0.876         0.835     0.634     1                                                                                
  MgVol         0.900         0.866     0.677     0.998     1                                                                      
  CMR           0.967         0.958     0.832     0.956     0.972     1                                                            
  AMR           0.968         0.960     0.836     0.954     0.970     1.000     1                                                  
  PolarizG      0.964         0.954     0.823     0.961     0.975     1.000     1.000     1                                        
  TPSA          0.270         0.189     --0.125   0.667     0.631     0.437     0.430     0.450      1                             
  HBA           0.270         0.189     --0.125   0.667     0.631     0.437     0.430     0.450      1.000     1                   
  nCL           --0.102       0.008     0.305     --0.540   --0.490   --0.270   --0.263   --0.286    --0.936   --0.936   1         
  nBR           0.648         0.570     0.301     0.928     0.903     0.778     0.773     0.788      0.871     0.871     --0.816   1
  log *P*       --0.891       --0.894   --0.731   --0.921   --0.933   --0.940   --0.939   --0.941    --0.499   --0.499   0.326     --0.777

###### 

PBDE levels in human milk and blood samples from different countries.

                                                                                      ΣPBDE (ng/g lipid)                                                                                                                               
  ---------------- ----------------------------------------------------- ------------ -------------------- ------ ------ ------------------------------------------------------------------------------------------------------------- -----------------------
  Japan                                                                                                                                                                                                                                
   Milk            105                                                   2004         2.54                 1.28          28, 47, 99, 100, 153, 154                                                                                     [@b5-ehp0114-001179]
   Milk            89                                                    2005         1.74                 1.54   0.12   15, 28, 47, 99, 100, 153, 154, 183, 196, 197, 206, 207, 209                                                   Present study
   Serum           40                                                    1995         1.8                  1.3           47, 99, 100, 153                                                                                              [@b15-ehp0114-001179]
   Serum           89                                                    2005         3.34                 2.99   1.20   15, 28, 47, 99, 100, 153, 154, 183, 196, 197, 206, 207, 209                                                   Present study
   Milk            12                                                    1999         1.72                               28, 47, 99, 153, 154                                                                                          [@b25-ehp0114-001179]
   Milk            1(27)[a](#tfn4-ehp0114-001179){ref-type="table-fn"}   2000         1.39                        0.04   28, 37, 47, 66, 75, 77, 85, 99, 100, 138, 153, 154, 183                                                       [@b2-ehp0114-001179]
   Blood           156                                                   1999--2001   13                   6.9    9.20   3, 7, 15, 17, 28, 47, 49, 66, 71, 77, 85, 99, 100, 119, 126, 138, 139, 153, 154, 183, 209                     [@b41-ehp0114-001179]
   Milk            4                                                     2003         1.04                               17, 25, 28, 30, 32, 33, 35, 37, 47, 49, 66, 71, 75, 77, 85, 99, 100, 116, 119, 126, 138, 153, 154, 155, 166   [@b11-ehp0114-001179]
   Blood           4                                                     2003         0.3                                17, 25, 28, 30, 32, 33, 35, 37, 47, 49, 66, 71, 75, 77, 85, 99, 100, 116, 119, 126, 138, 153, 154, 155, 166   [@b11-ehp0114-001179]
  United States                                                                                                                                                                                                                        
   Milk            47                                                    2002         73.9                 34     0.92   28, 47, 99, 100, 153, 154                                                                                     [@b32-ehp0114-001179]
   Milk            16                                                    2004         77.5                 48.5   0.38   28, 32, 33, 47, 66, 71, 85, 99, 100, 153, 154, 183, 209                                                       [@b34-ehp0114-001179]
   Serum           93                                                    2001--2003   24.6                               47, 85, 99, 100, 153, 154, 183                                                                                [@b22-ehp0114-001179]
   Serum           7                                                     2000--2002                        61            17, 28, 47, 66, 85, 99, 100, 153, 154, 183, 203, 209                                                          [@b37-ehp0114-001179]
   Serum           12                                                    2001                              37            47, 99, 100, 153, 154, 183                                                                                    [@b20-ehp0114-001179]
  Canada                                                                                                                                                                                                                               
   Milk            10                                                    1992         5.65                 3.03          28, 47, 99, 100, 153                                                                                          [@b28-ehp0114-001179]
   Milk            98                                                    2001--2002   22                                 28, 47, 99, 100, 153                                                                                          [@b26-ehp0114-001179]
   Plasma          10                                                    1994--1999   23.3                 20.3          28, 47, 85, 99, 100, 153, 154, 183                                                                            [@b29-ehp0114-001179]
  Mexico                                                                                                                                                                                                                               
   Milk            7                                                     2003         4.4                         0.30   47, 99, 100, 153, 154, 209                                                                                    [@b19-ehp0114-001179]
   Plasma          5                                                     2003         29.1                        9.50   47, 99, 100, 153, 154, 209                                                                                    [@b19-ehp0114-001179]
  United Kingdom                                                                                                                                                                                                                       
   Milk            54                                                    2001--2003   8.9                  6.3           17, 28, 32, 35, 37, 47, 49, 71, 75, 85, 99, 100, 119, 153, 154                                                [@b14-ehp0114-001179]
  Sweden                                                                                                                                                                                                                               
   Milk            93                                                    1996--1999   4.01                 3.15          47, 99, 100, 153, 154                                                                                         [@b18-ehp0114-001179]
   Serum           20                                                    1997                              3.3           47, 153, 154, 183, 209                                                                                        [@b36-ehp0114-001179]
   Milk            15                                                    2000--2001                        2.14          17, 28, 47, 66, 85, 99, 100, 153, 154, 183                                                                    [@b10-ehp0114-001179]
   Plasma          15                                                    2000--2001                        2.07          17, 28, 47, 66, 85, 99, 100, 153, 154, 183                                                                    [@b10-ehp0114-001179]
  Norway                                                                                                                                                                                                                               
   Serum           1(29)[a](#tfn4-ehp0114-001179){ref-type="table-fn"}   1999         3.34                               28, 47, 99, 100, 153, 154                                                                                     [@b42-ehp0114-001179]
  Finland                                                                                                                                                                                                                              
   Milk            11                                                    1994--1998   2.25                 1.62          28, 47, 99, 153                                                                                               [@b39-ehp0114-001179]
  Germany                                                                                                                                                                                                                              
   Milk            93                                                    2001--2003   2.23                 1.78   0.17   28, 47, 99, 153, 154, 183, 209                                                                                [@b43-ehp0114-001179]
  Netherlands                                                                                                                                                                                                                          
   Serum           78                                                    2001--2002   10.7                 9.3           47, 99, 100, 153, 154                                                                                         [@b46-ehp0114-001179]
  Spain                                                                                                                                                                                                                                
   Milk            15                                                    2002         2.41                 1.7           15 congeners                                                                                                  [@b33-ehp0114-001179]
  Italy                                                                                                                                                                                                                                
   Milk            4(40)*^a^*                                            2000--2001   2.75                               28, 47, 66, 85, 99, 100, 138, 153, 154, 183                                                                   [@b12-ehp0114-001179]

The numbers of pooled samples are shown in parentheses.
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